Key statistics
As of last trade Allakos Inc (37Z:FRA) traded at 0.483, 0.84% above its 52-week low of 0.479, set on Sep 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.483 |
---|---|
High | 0.483 |
Low | 0.483 |
Bid | 0.4781 |
Offer | 0.4973 |
Previous close | 0.5056 |
Average volume | 1.33k |
---|---|
Shares outstanding | 88.85m |
Free float | 86.78m |
P/E (TTM) | -- |
Market cap | 48.16m USD |
EPS (TTM) | -2.35 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 07:05 BST.
More ▼
Announcements
- Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
- Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
- Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
- Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
- Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
- Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
- Allakos Announces a Restructuring to Focus on Development of AK006
- Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
- Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
More ▼